On this page of StockholderLetter.com we present the latest annual shareholder letter from FATE THERAPEUTICS INC — ticker symbol FATE. Reading current and past FATE letters to shareholders can bring important insights into the investment thesis.
Better Cells For Better Therapies 2024 Annual Report Dedicated to bringing a first-in-class pipeline of iPSCderived cellular immunotherapies to patients T cells | NK cells | CD34+ cells induced Pluripotent Stem Cell Platform a renewable source for off-the-shelf engineered cell products
 • shareholder letter icon 4/17/2025 Letter Continued (Full PDF)
 • stockholder letter icon 4/21/2023 FATE Stockholder Letter
 • stockholder letter icon 4/26/2024 FATE Stockholder Letter
 • stockholder letter icon More "Biotechnology" Category Stockholder Letters
 • Benford's Law Stocks icon FATE Benford's Law Stock Score = 84


FATE Shareholder/Stockholder Letter Transcript:

Better Cells For Better Therapies  
2024 Annual Report
Dedicated to bringing a first-in-class pipeline of iPSCderived cellular immunotherapies to patients
T cells | NK cells | CD34+ cells
induced Pluripotent Stem Cell Platform
a renewable source for off-the-shelf engineered cell products




shareholder letter icon 4/17/2025 Letter Continued (Full PDF)
 

FATE Stockholder/Shareholder Letter (FATE THERAPEUTICS INC) | www.StockholderLetter.com
Copyright © 2023 - 2026, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.